Mandate

VINGE ADVISES IK VII FUND IN CONNECTION WITH ACQUISITION OF TELECOMPUTING FROM FERD CAPITAL

January 15, 2016

Vinge and the Norwegian law firm, Wiersholm are advising the IK VII Fund in connection with its investment in TeleComputing AS. The TeleComputing Group is a fast-growing supplier of complete IT solutions on the Nordic SMB market. TeleComputing provides market-leading and environmentally friendly solutions within IT operations management, outsourcing, IT OnDemand, cloud services and Software as a Service (SaaS) services. The subsidiary, Kentor conducts system integration operations and provides qualified industry and operations specialists, systems developers and IT advisory services. The group has 860 employees at nine locations in four countries and has approximately 850 corporate customers in the Nordic region. The transaction is subject to customary closing conditions.

Vinge’s team consists of partner Jonas Bergström together with, among others, counsel Ulrich Ziche and associates Carl Sander, Joacim Rydergård, Sara Strandberg, Josefine Lanker, Karl-Johan Alvarsson and Joel Wahlberg and project assistant Caroline Skymberg. Partner Pär Remnelid and associate Ina Lunneryd are advising on the competition law regulatory aspects of the transaction.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025